Evidence map›Paper›PMID 35113888›Full record

ArticlePLoS neglected tropical diseases2022

Costs of mass drug administration for scabies in Fiji.

Maria Mow, Li Jun Thean, Matthew Parnaby, Jyotishna Mani, Eric Rafai, Aalisha Sahukhan, Mike Kama, Meciusela Tuicakau, Joseph Kado, Lucia Romani and 5 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Maria MowTropical Diseases Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.ORCID 0000-0001-7301-0160
Li Jun TheanTropical Diseases Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.ORCID 0000-0002-6231-5265
Matthew ParnabyTropical Diseases Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
Jyotishna ManiTropical Diseases Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.ORCID 0000-0001-5035-8076
Eric RafaiMinistry of Health and Medical Services, Suva, Fiji.
Aalisha SahukhanMinistry of Health and Medical Services, Suva, Fiji.
Mike KamaMinistry of Health and Medical Services, Suva, Fiji.
Meciusela TuicakauMinistry of Health and Medical Services, Suva, Fiji.ORCID 0000-0002-3403-3623
Joseph KadoMinistry of Health and Medical Services, Suva, Fiji.
Lucia RomaniKirby Institute, University of New South Wales, Sydney, New South Wales, Australia.ORCID 0000-0001-9038-5300
Daniel EngelmanTropical Diseases Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.ORCID 0000-0002-4909-1287
Margot WhitfeldDepartment of Dermatology, St. Vincent's Hospital, Sydney, New South Wales, Australia.ORCID 0000-0003-4509-4461
John KaldorKirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
Andrew SteerTropical Diseases Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.ORCID 0000-0001-7346-0196
Natalie CarvalhoSchool of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0002-5599-2209
Ministry Of Health · FJMurdoch Children's Research Institute · AUUNSW Sydney · AURoyal Children's Hospital · AUThe University of Melbourne · AUThe Kids Research Institute Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2019, the Murdoch Children's Research Institute in partnership with the Fiji Ministry of Health and Medical Services carried out an integrated mass drug administration (MDA) for the treatment of scabies and lymphatic filariasis in the Northern Division of Fiji (population estimate 131,914). We conducted a retrospective micro-costing exercise focused on the cost of scabies control in order to inform budgeting and policy decision making in an endemic setting. We collected detailed information on financial and economic costs incurred by both parties during the course of the MDA campaign (April 2018 to July 2019). We also conducted interviews with personnel involved in the financial administration of the MDA campaign. The economic cost of delivering two doses of ivermectin was US$4.88 per person. The cost of donated drugs accounted for 36.3% of total MDA costs. In this first large-scale MDA for the public health control of scabies, the estimated cost of delivering MDA per person for scabies was considerably more expensive than the costs reported for other neglected tropical diseases. The important cost drivers included the remuneration of health care workers who were extensively involved in the campaign, coverage of hard-to-reach, mainly rural populations and the two-dose regimen of ivermectin. These results highlight the importance of these cost determinants and can be used to plan current and future MDA programs.

Indexed as

Elephantiasis, FilarialFijiHumansIvermectinMass Drug AdministrationNeglected DiseasesScabiesIvermectin

Identifiers

PMID35113888
PMCPMC8846527
OpenAlexW4210300866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.